Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Redhill Biopharma Ltd. - American Depositary Shares
(NQ:
RDHL
)
1.360
+0.050 (+3.82%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Redhill Biopharma Ltd. - American Depositary Shares
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib
April 11, 2022
Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The...
From
RedHill Biopharma Ltd
Via
AccessWire
64 Biggest Movers From Yesterday
↗
March 18, 2022
Gainers Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership with The Walt Disney Co. Cuentas Inc. (NASDAQ:...
Via
Benzinga
RedHill, Kukbo Ink Oral Opaganib Licensing Pact For COVID-19 In South Korea
↗
March 15, 2022
Via
Benzinga
Redhill Biopharma: Q4 Earnings Insights
↗
March 17, 2022
Redhill Biopharma (NASDAQ:RDHL) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement....
Via
Benzinga
Earnings Scheduled For March 17, 2022
↗
March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is...
Via
Benzinga
Redhill Biopharma's Earnings: A Preview
↗
March 16, 2022
Redhill Biopharma (NASDAQ:RDHL) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
RedHill Biopharma's Upamostat Shows 100% Efficacy In Non-Hospitalized COVID-19 Patients
↗
March 01, 2022
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced topline results from the Phase 2 part of the Phase 2/3 study of RHB-107 (upamostat) in non-hospitalized...
Via
Benzinga
RedHill Biopharma's COVID-19 Antiviral Cuts Mortality By 70% In Remdesivir Treated Patients
↗
February 07, 2022
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced results from two recently completed prespecified analyses from the oral opaganib Phase 2/3 study in hospitalized severe COVID-19.
Via
Benzinga
18 Stocks Moving in Friday's Pre-Market Session
↗
January 14, 2022
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) shares rose 17.6% to $0.8350 in pre-market trading after dropping around 9% on Thursday. NextPlay Technologies, Inc...
Via
Benzinga
RedHill Biopharma's Oral COVID-19 Treatment Improves Median Time To Viral RNA Clearance
↗
January 13, 2022
RedHill Biopharma Ltd (NASDAQ: RDHL) announced new data from a prespecified analysis of all oral opaganib's Phase 2/3 study patients in COVID-19 patients. The...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
March 15, 2022
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...
Via
Benzinga
63 Biggest Movers From Yesterday
↗
December 31, 2021
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
December 30, 2021
Gainers Kiora Pharmaceuticals (NASDAQ:KPRX
Via
Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
↗
December 30, 2021
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors. Future...
Via
Benzinga
RedHill Announces Additional Insider Buying
December 15, 2021
RALEIGH, NC and TEL-AVIV, ISRAEL / ACCESSWIRE / December 15, 2021 / RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that...
From
RedHill Biopharma Ltd
Via
AccessWire
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
↗
December 14, 2021
Photo by Chris Montgomery on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
RedHill Biopharma's Talicia Recommended For H. Pylori Infection
↗
December 09, 2021
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced the publication of a new study revealing concerning rates of widespread, physician-directed prescribing of...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
December 09, 2021
Good morning, trader! It's time to kick off another busy day of trading with the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
RedHill Biopharma Ltd Announces Concerning Clarithromycin Rx Rates for H. pylori
December 09, 2021
RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication Despite increasing...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
RedHill Biopharma Says Opaganib Mechanism Against COVID-19 Not Impacted By Omicron Mutations
↗
December 06, 2021
RedHill Biopharma Ltd (NASDAQ: RDHL) announced that opaganib's proposed mechanism of action is not impacted by spike protein mutations. Opaganib is expected to be...
Via
Benzinga
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
December 07, 2021
Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not...
Via
FinancialNewsMedia
RedHill Biopharma Ltd - Opaganib MoA Not Impacted by Omicron Mutations
December 06, 2021
Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
RedHill Biopharma's Talicia For Bacterial Infections Shows Efficacy Irrespective of Patient BMI
↗
December 02, 2021
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced the publication of a new study of Talicia to treat H. pylori infection. The new publication, describing a ...
Via
Benzinga
RedHill Biopharma Ltd Announces Talicia: Consistent Efficacy Irrespective of BMI
December 02, 2021
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI High Body Mass Index and obesity are known risk factors for H. Pylori eradication...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
RedHill’s Movantik Added To Medicare Formulary
December 01, 2021
RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans Movantik® approved for inclusion as preferred and unrestricted...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
↗
November 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-...
Via
Benzinga
RedHill Reports 3Q/2021 Financial Results
November 30, 2021
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Earnings Scheduled For November 30, 2021
↗
November 30, 2021
Companies Reporting Before The Bell • Hello Gr (NASDAQ:MOMO) is estimated to report quarterly earnings at $0.31 per share on revenue of $573.63 million. • UP...
Via
Benzinga
Earnings Preview For Redhill Biopharma
↗
November 29, 2021
Redhill Biopharma (NASDAQ:RDHL) is set to give its latest quarterly earnings report on Tuesday, 2021-11-30. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
52 Biggest Movers From Friday
↗
November 22, 2021
Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland Technologies highlighted the launch of second...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.